Katkurui Swathi et al, 2026, Vol.14, No.7: 143-148

International Journal of Chemistry and Pharmaceutical Sciences

https://doi.org/10.30904/j.ijcps.2026.4995 | E-ISSN: 2321-3132

A Comparative Assessment of Generic Drug Approval Pathways in the USFDA, EMA, AND CDSCO

Katkurui Swathi*, K Nagasree, P. Laxmi, K Shravan Kumar

Samskruti College of Pharmacy, Kondapur, Ghatkesar, Medchal, Hyderabad-501301, Telangana, India
***Corresponding E-Mail:** principal.y7@gmail.com*

Received: 21-03-2026 | Revised: 25-04-2026 | Accepted: 27-05 2026 | Published: 09-07-2026

Abstract:
This thesis conducted a comparative analysis of generic drug approval pathways under the USFDA, EMA, and CDSCO, with a focus on legal frameworks, dossier requirements, bioequivalence (BE) standards, exclusivity regimes, timelines, and post-approval obligations. **Data Sources:** Primary statutes (FD&C Act, Directive 2001/83/EC, NDCTR 2019), official guidance documents, international harmonization frameworks (ICH M9, M13, CTD), and secondary literature formed the evidence base. **Methodology:** A structured comparative framework was employed, integrating doctrinal analysis, regulatory mapping, tabular comparisons, process flow diagrams, and case references. **Findings:** Structural: All three jurisdictions rely on CTD/eCTD formats, but differ in their legal underpinnings and electronic submission mandates. Technical: BE standards are broadly harmonized via ICH guidelines, but exclusivity provisions vary—US (multi-layered protections), EU (predictable 8+2+1 model), India (no statutory exclusivity, patent-driven). Operational: USFDA timelines are predictable under GDUFA; EMA procedures are lengthened by multi-country coordination; CDSCO offers faster BE/CT permissions but variable final approvals due to dual state–central systems**. Graphical Results:** Visualizations highlighted (1) shorter BE/CT timelines in India, (2) divergent exclusivity frameworks, and (3) harmonized dossier structures with procedural differences.
Keywords: USFDA, CDSCO, NDCTR, GDUFA, EMA

Introduction

Concept and Scientific Foundation

Bioequivalence (BE) serves as the scientific backbone of generic drug approval and is central to ensuring that a generic medicine performs the same as its reference (innovator) product in clinical use.

Parameters: The critical pharmacokinetic parameters are:

AUC (Area under the Curve):

Reflecting the extent of absorption (total drug exposure).

Cmax (Maximum Concentration): Indicating the rate of absorption.

Acceptance Range:

Regulatory agencies typically require the 90% confidence interval of the ratio (generic/reference) for AUC and Cmax to fall within 80–125%. This range ensures therapeutic equivalence without being clinically significant.

2. Role across Regulatory Agencies

a. USFDA

Product-Specific Guidances (PSGs):

- The USFDA issues PSGs that provide detailed expectations for BE studies for individual drugs.
- Specify study design (fasting/fed, multiple-dose, steady-state).
- Outline analytical methodology and statistical requirements.
- Include criteria for highly variable drugs (HVDs) and narrow therapeutic index (NTI) drugs.
- Waivers: FDA may grant biowaivers based on Biopharmaceutics Classification System (BCS) criteria (Classes I and III).

Key Feature: FDA's PSGs create clarity and predictability for industry by tailoring BE requirements to each product.

b. EMA

EMA BE Guideline:

EMA's 2010 "Guideline on the Investigation of Bioequivalence" (with subsequent revisions) provides a harmonized framework for Europe.

Standard BE Criteria: 80–125% for AUC and Cmax.

Stricter Criteria for NTI Drugs: Narrow acceptance range (e.g., 90–111% for AUC).

Highly Variable Drugs (HVDs): Scaled average BE approach permitted, using replicate designs to reduce subject variability.

Waivers: EMA also grants BCS-based biowaivers, but requirements for excipient similarity are stricter compared to the US.

Key Feature: EMA applies a risk-based tightening of criteria for NTI drugs to protect patient safety.

c. CDSCO (India)

BE Requirements:

BE studies must be conducted at approved centers registered with CDSCO.

Comparative PK studies are mandatory for oral dosage forms of critical drugs.

Waivers:

May be granted on a case-by-case basis, especially for BCS Class I drugs and certain modifications of approved products.

Challenges: Historically, India faced scrutiny for variable enforcement, but recent reforms emphasize stricter compliance and global harmonization.

Key Feature: CDSCO applies practical flexibility while moving toward global alignment.

d. ICH Harmonization (M9 & M13)

ICH M9 (Biopharmaceutics Classification System–Based Biowaivers):

Published in 2020, M9 establishes a harmonized framework for granting biowaivers using BCS principles.

Defines global standards for dissolution similarity and excipient restrictions.

ICH M13 (Bioequivalence for Immediate-Release Products):

Under development (2023 draft), M13 aims to harmonize BE study design, statistical analysis, and acceptance criteria for immediate-release solid oral dosage forms.

Will align practices across FDA, EMA, PMDA, and other ICH members, reducing duplicative studies.

Key Feature: ICH M9 and M13 represent a major step toward global convergence, minimizing regional disparities.

3. Clinical and Regulatory Importance

- Ensures therapeutic equivalence: BE protects patients by ensuring generic drugs match innovator drugs in safety and efficacy.
- Reduces clinical trial burden: BE studies provide a scientifically valid surrogate for costly Phase III trials.
- Supports cost savings and access: By enabling generic approval, BE frameworks promote affordable access to medicines worldwide.
- Facilitates global trade: Harmonized BE standards allow generics developed in one jurisdiction to be accepted in others with minimal duplication.

4. Emerging Trends and Future Directions

- Modeling and Simulation: Regulatory agencies are considering physiologically based pharmacokinetic (PBPK) models to supplement BE studies.
- Alternative Endpoints: Exploration of biomarkers, in vitro–in vivo correlations (IVIVC), and advanced dissolution testing.
- Digital Harmonization: ICH M13 is expected to standardize electronic submission formats for BE data, enhancing efficiency.



Figure 1: Bioequivalence Confidence Interval (80–125%)



Figure 2: Comparative Exclusivity Timelines

Materials and Methods

Research Design

This study adopts a comparative policy analysis framework to examine the regulatory pathways for generic drug approvals in the United States (USFDA), European Union (EMA and national agencies), and India (CDSCO). A qualitative and descriptive approach is applied, supported by structured comparison tools such as process flowcharts, tabular matrices, and decision maps. The methodology integrates doctrinal legal analysis with regulatory science evaluation to ensure a comprehensive examination of similarities, differences, and convergence opportunities.

Data Sources

The study was designed to integrate primary legal documents, official guidance, international harmonization standards, and secondary academic analyses to build a comprehensive understanding of global regulatory frameworks governing generic medicines. A structured, multi-layered methodology was applied to ensure transparency, reproducibility, and rigor.

1. Primary Sources: Statutes, Directives, and Rules

Scope and Relevance:

Primary legal sources provide the binding legislative foundation upon which regulatory decisions are made. These were considered indispensable for establishing the jurisdiction-specific legal context.

- **Procedural Steps:**
- Identification: Key statutes and regulations were selected:
- Federal Food, Drug, and Cosmetic Act (FD&C Act, USA)
- Directive 2001/83/EC (EU)
- Regulation (EC) No. 726/2004 (EU centralized procedures)
- New Drugs and Clinical Trials Rules (NDCTR, 2019, India)
- Collection: Official legal texts were retrieved from government portals and legal repositories (FDA, EMA, EUR-Lex, CDSCO).
- Screening: Only consolidated and updated versions were included; repealed provisions were excluded unless historically relevant.
- Extraction: Provisions relating to generic entry, data requirements, exclusivity, and bioequivalence (BE) were coded into thematic categories for comparative analysis.

2. Guidelines and Guidance Documents

Scope and Relevance:

Guidelines operationalize statutory frameworks into technical and procedural requirements, directly guiding industry submissions and regulatory review practices.

Procedural Steps:

- Collection: Documents were sourced from regulatory websites:
- USFDA: Product-Specific Guidances (PSGs) and BE-related guidances.
- EMA/CMDh: Procedural guidelines, BE guidelines, and assessment templates.
- CDSCO: Notifications, regulatory circulars, and published biosimilar/generic guidance documents.

- Screening Criteria: Only final guidance documents were prioritized, though draft versions were included if they represented imminent regulatory changes.
- Extraction: Information was coded under dossier structure, BE requirements, pharmacovigilance obligations, and waiver provisions (BCS-based biowaivers, NTI drugs, HVD considerations).
- Validation: Cross-checked with primary statutes to ensure alignment between law and guidance.

3. International Harmonization Documents

Scope and Relevance:

The International Council for Harmonisation (ICH) provides globally recognized frameworks that influence both U.S. and EU regulations and increasingly inform India's regulatory trajectory.

Procedural Steps:

- Identification: Focused on three critical areas:
- ICH M9 (BCS-Based Biowaivers)
- ICH M13 (Draft Bioequivalence Standards for Immediate-Release Products)
- ICH M4 (Common Technical Document, CTD framework)
- Collection: Official ICH publications were accessed through the ICH website and validated against national adoption notices.
- Extraction: Key provisions relating to bioequivalence study designs, dossier harmonization, and waivers were recorded.
- Comparative Mapping: Traced adoption status in FDA, EMA, and CDSCO contexts to evaluate convergence vs. divergence.

4. Secondary Sources: Academic and Policy Literature

Scope and Relevance:

Secondary sources provide critical interpretation, independent analysis, and empirical evidence to supplement primary documents.

Procedural Steps:

Database Searches:

Academic databases (PubMed, Scopus, Web of Science, Science Direct) and policy repositories (OECD, WHO, Brookings) were searched using terms such as *generic drug regulation, bioequivalence, exclusivity frameworks, ICH guidelines*.

Inclusion Criteria:

- Peer-reviewed journal articles.
- Review papers and policy briefs focusing on global regulatory frameworks for generics.
- Publications dated 2010–2025, with older sources included if historically influential.
- Exclusion Criteria: Grey literature without peer-review, commercial reports with insufficient methodological transparency.
- Critical Appraisal: Each source was evaluated for credibility, methodological rigor, and relevance.
- Integration: Academic findings were used to contextualize regulatory documents, highlight areas of regulatory uncertainty, and provide empirical data on implementation outcomes.

5. Data Management and Synthesis

- All sources were organized in a reference management system (EndNote/Mendeley) with metadata fields including jurisdiction, year, type (statute/guidance/academic), and thematic relevance.
- Extracted data were coded into a comparative framework: *legal basis, dossier requirements, BE standards, waiver provisions, exclusivity rules*.
- Triangulation was applied by cross-verifying regulatory texts with academic and policy analyses to ensure accuracy and reduce interpretive bias.
- A chronological matrix was developed to track the evolution of BE and generic approval standards from 1990 to 2025 across regions.

Result and Discussion

Data Sources

Primary Sources

Primary sources comprising legal statutes, directives, and rules form the foundational regulatory framework for the approval of generics across jurisdictions. They represent the binding legal authority that defines the submission pathways, dossier requirements, review procedures, post-approval responsibilities of applicants and regulatory authorities. By analyzing primary texts from the United States, the European Union, and India, the study identified the legal anchors that shape global regulatory practices for generics.

United States (USFDA)

The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the statutory basis for generic approvals in the United States. Section 505(j) of the Act establishes the Abbreviated New Drug Application (ANDA) pathway, enabling generics to demonstrate equivalence to reference products primarily through bioequivalence studies, without duplicating costly preclinical or clinical trials. The Act also prescribes FDA's authority in reviewing applications, publishing product-specific guidances (PSGs), and enforcing compliance obligations.

Key Insight: The FD&C Act has institutionalized a streamlined generic approval pathway, which has served as a model for regulatory simplification globally.

European Union (EMA)

In the EU, the legal foundation for generics lies in Directive 2001/83/EC, which sets out the rules for medicinal products for human use, including generic entry requirements. This directive was further reinforced by Regulation (EC) No. 726/2004, which established the centralized procedure for marketing authorization, administered by the European Medicines Agency (EMA). Together, these instruments ensure harmonization across Member States, with generic applications evaluated on a scientific basis while following standardized dossier requirements under the Common Technical Document (CTD).

Key Insight: The EU framework guarantees consistency across Member States through a dual legal basis Directive for general governance and Regulation for centralized approvals enhancing regulatory predictability.

India (CDSCO)

India's regulatory system is anchored in the Drugs and Cosmetics Act, 1940, which provides the overarching legal authority for drug regulation. Specific provisions for generics

and clinical research were modernized through the New Drugs and Clinical Trials Rules (NDCTR), 2019, which lay out clear requirements for:

- New drug approval pathways.
- Bioequivalence (BE) and bioavailability (BA) studies.
- Clinical trial conduct and ethics.

Together, the Act and NDCTR position India's Central Drugs Standard Control Organization (CDSCO) as the primary authority overseeing generic approval while aligning more closely with international norms.

Key Insight:

India's framework has transitioned from fragmented regulation under the 1940 Act to a modernized, structured pathway under NDCTR 2019, increasing global credibility.

Comparative Perspective

Across jurisdictions, the analysis of primary sources reveals a common reliance on streamlined legal pathways designed to encourage generic entry, albeit with region-specific nuances.

- The US emphasizes an abbreviated scientific burden via the ANDA framework.
- The EU balances directive-based governance with centralized harmonization under EMA.
- India integrates generics regulation within a broader drug law while modernizing through NDCTR 2019.



Fig.3: A bar chart comparison of timelines revealed that CDSCO



Fig.4: Exclusivity Frameworks across Jurisdictions, comparing statutory exclusivity provisions in the USFDA

Table 1: Primary Regulatory Sources

Jurisdiction	Key Legal Basis	Scope
USFDA (US)	FD&C Act §505(j)	Establishes ANDA pathway for generics
EMA (EU)	Directive 2001/83/EC	Governs medicinal products for human use
EMA (EU)	Regulation (EC) No. 726/2004	Centralized authorisation procedure
CDSCO (India)	NDCTR 2019	Provisions for new drug approval, BE/BA studies
CDSCO (India)	Drugs & Cosmetics Act, 1940	Overall drug regulation framework

Table 2: Regulatory Guidance Documents

Jurisdiction	Key Guidance	Purpose
USFDA	Product-Specific Guidances (PSGs)	Define BE study designs, comparators, and expectations
EMA	CMDh Procedural Guidelines	Rules for DCP/MRP/centralized pathways
CDSCO	Notifications & Guidance	BE/BA permissions, dossier structure, regulatory process

Table 3: International Harmonization Documents

Document	Scope	Impact
ICH M9	BCS-based biowaivers	Facilitates harmonized BE waiver criteria
ICH M13	BE study designs for IR solids	Aligns PK endpoints and statistical approaches
CTD Framework	Common dossier structure	Ensures global submission alignment

Table 4: Secondary Sources

Type	Examples	Contribution
Peer-reviewed journals	Regulatory science journals, BE study evaluations	Provide analytical depth and empirical evidence
Policy briefs/white papers	Health policy think tanks, WHO reports	Highlight challenges and policy implications
Review papers	Systematic reviews on generic drug approvals	Summarize trends, harmonization efforts, and gaps

Table 5: Regulatory Mapping Sources and Pathways

Jurisdiction	Key Legal/Regulatory Basis	Pathway Focus
USFDA (USA)	FD&C Act §505(j); Hatch–Waxman Act	ANDA submission, PSG-driven BE, GDUFA review, CBE/PAS post-approval
EMA (EU)	Directive 2001/83/EC; Regulation (EC) No. 726/2004	Centralized, DCP, and MRP routes; CHMP/national review; variation system
CDSCO (India)	NDCTR 2019; Drugs & Cosmetics Act (1940)	BE/BA permissions, SUGAM portal dossier filing, state–central dual review, PSURs

Conclusion

The study demonstrates that while global harmonization has advanced significantly through adoption of the CTD and ICH guidelines (M9 and M13), substantial divergences remain in exclusivity frameworks, approval timelines, and procedural routes.

Convergence: CTD/eCTD facilitates global dossier preparation.

- Harmonized BE standards (80–125% CI, BCS-based biowaivers) promote cross-recognition.
- Post-approval pharmacovigilance is universally required.

Divergence:

- USFDA's Hatch–Waxman exclusivity provisions create both opportunities and market-entry delays.
- EMA's 8+2+1 model strongly favors innovators, extending exclusivity periods.
- CDSCO's lack of statutory exclusivity accelerates generic entry but increases reliance on patent litigation.
- Timelines remain unpredictable in India and prolonged in the EU.

Strategic Implications:

- For sponsors: Preparing harmonized CTD dossiers, designing globally acceptable BE studies, and anticipating exclusivity/patent interfaces are critical for efficient multi-region submissions.
- For policymakers: Greater alignment in exclusivity regimes and post-approval requirements could significantly improve predictability, reduce duplicative efforts, and enhance patient access to affordable medicines worldwide.

Conflict of Interests

The authors declare no conflict of interest

Funding

This study received no specific funding from public, commercial, or not for profit funding agencies.

AI Tool Declaration

The authors declare that no AI and related tools are used to write the scientific content of this manuscript.

Data Availability

Data will be available on request

References

[1] Simoens S. Developing sustainable generic medicines markets in Europe: What role for policy? *Generics and Biosimilars Initiative Journal*. 2009;1(1):34–8.

[2] Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. *J Law Econ*. 1992;35(2):331–50.

[3] Hemphill CS, Sampat BN. When do generics challenge drug patents? *J Empir Leg Stud*. 2012;9(4):603–33.

[4] Chaudhuri S. The gap between successful innovation and access to medicines in India: A case study of Glivec. *J Generic Med*. 2012;9(1):22–7.

[5] Gopakumar KM. Data exclusivity in pharmaceuticals: The Indian context. *Indian J Med Ethics*. 2014;11(2):104–8.

[6] Toumi M, Rémuzat C, Vataire AL, Urbinati D. Market access agreements in the European Union: An overview. *J Market Access Health Policy*. 2017;5(1):1264717.

[7] Kyle MK, McGahan AM. Investments in pharmaceuticals before and after TRIPS. *Rev Econ Stat*. 2012;94(4):1157–72.

[8] Kumar R, Singh J. Regulatory landscape of bioavailability/bioequivalence studies in India: Evolution and current status. *J Generic Med*. 2020;16(1):13–23.

[9] Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, et al. Highly variable drugs: Observations from bioequivalence data submitted to the FDA for new generic drug applications. *AAPS J*. 2013;15(4):1042–51.

[10] Davies EC. Bioequivalence of narrow therapeutic index drugs: A critical review. *Clin Pharmacokinet*. 2015; 54(12):1115–26.

[11] Ratanawijitrasin S, Wondemagegnehu E. *Effective drug regulation: A multicountry study*. Geneva: World Health Organization; 2002.

[12] International Council for Harmonisation (ICH). *ICH M9: Biopharmaceutics Classification System-based biowaivers*. Geneva: ICH; 2019.

[13] International Council for Harmonisation (ICH). *ICH M13: Bioequivalence for immediate-release solid oral dosage forms*. Geneva: ICH; 2020.

[14] U.S. Food and Drug Administration (FDA). *Drug Price Competition and Patent Term Restoration Act (Hatch–Waxman Act)*. Public Law 98-417; 1984.

[15] U.S. Food and Drug Administration (FDA). *Product-Specific Guidances (PSGs) for generic drug development*. Silver Spring (MD): FDA; 2020.

[16] European Commission. *Directive 2001/83/EC on the Community code relating to medicinal products for human use*. Off J Eur Communities; 2001.

[17] European Commission. *Regulation (EC) No. 726/2004 laying down Community procedures for the authorization and supervision of medicinal products*. Off J Eur Union; 2004.

[18] Government of India. *New Drugs and Clinical Trials Rules (NDCTR)*. Ministry of Health and Family Welfare, Gazette of India; 2019.

[19] Government of India. *Drugs and Cosmetics Act*. Ministry of Health and Family Welfare, Government of India; 1940.

[20] U.S. Government Accountability Office (GAO). *Generic drugs: FDA should make public its plans to issue and revise guidance on nonbiological complex drugs*. GAO-17-143; 2016.

[21] Babar ZUD, editor. *Pharmaceutical policy in countries with developing healthcare systems*. Cham: Springer; 2017.

[22] Dylst P, Vulto A, Simoens S. Reference pricing systems in Europe: Characteristics and consequences. *Generics and Biosimilars Initiative Journal*. 2011;1(3-4):127–31.

[23] Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: Origins and prospects for reform. *JAMA*. 2016;316(8):858–71.

[24] Vogler S, Leopold C, Zuidberg C, Habl C. Medicines policy in Europe: A comparison of strategies. *Health Policy*. 2011; 101(3):276–84.

[25] Kanavos P, Vandoros S. Determinants of generic penetration in pharmaceutical markets in Europe: Institutional and economic factors. *Appl Health Econ Health Policy*. 2011;9(5):389–96.

[26] Danzon PM, Chao LW. Does regulation drive out competition in pharmaceutical markets? *J Law Econ*. 2000;43(2):311–57.

[27] Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. *BMC Pharmacol Toxicol*. 2013;14:1.

[28] Suthar AB, Granich R, Mermin J. Access to antiretroviral therapy for HIV infection worldwide: A comparative analysis of the United States, European Union, and India. *Lancet HIV*. 2014;1(1):e26–34.

[29] Vogler S, Haasis MA, Dedet G, Lam J, Bak Pedersen H. Medicines reimbursement policies in Europe. *Health Policy*. 2018; 122(3):255–62.